Maintenance treatment for peripheral T-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study tests an experimental pill (SHR2554) as maintenance therapy after your first treatment for peripheral T-cell lymphoma has worked. The goal is to see if it helps keep the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You have a type of lymphoma called peripheral T-cell lymphoma (PTCL), including specific subtypes like ALCL, ENKTL, and others (but not cutaneous T-cell lymphoma).
- Your first round of chemotherapy must have worked well — your tumor shrank or disappeared (at least a partial response or better).
- You must be in reasonably good physical condition (able to do most daily activities).
- You must be willing to use highly effective birth control if there is any chance of pregnancy.
- You must not have other active cancers, serious infections, or conditions that affect swallowing or digestion.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two drugs, SHR2554 and liposomal mitoxantrone, as the first treatment for peripheral T-cell lymphoma (PTCL), a rare type of blood cancer. The goal is to see if this combination is safe and effective.
This trial tests a new drug called TR115 against the standard treatment options for people with peripheral T-cell lymphoma that has come back or hasn't responded to previous treatments. The goal is to see if TR115 can help shrink tumors and improve outcomes.
This trial tests a combination of three medicines (anti-PD-1, lenalidomide, and azacitidine) for adults with relapsed or refractory peripheral T-cell lymphoma (PTCL) that is measurable or growing. It aims to shrink lymphoma and improve control of the disease when standard treatments haven’t worked or have stopped working.
This trial tests a new drug called SHR2554 (compared to chidamide) for T-cell lymphoma that has not responded to or come back after prior treatment. It's a Phase 3 study to see if the drug can help control the cancer.
This trial tests a new combination of two pills—linperlisib and an EZH2 inhibitor—for people with a type of lymphoma called peripheral T-cell lymphoma (PTCL) that has come back or not responded to previous treatment. The goal is to see if this combination can help control the disease with manageable side effects.
This trial tests whether a daily pill called golidocitinib can keep your PTCL from coming back after you've had a good response to your first chemotherapy. The study compares the drug to a placebo (a pill with no active medicine) to see if it helps prevent relapse.
Hear when a new PTCL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.